Cellebrite DI Ltd. (NASDAQ:CLBT) Stake Boosted by Crescent Park Management L.P.

Crescent Park Management L.P. lifted its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 8.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,862,482 shares of the company’s stock after purchasing an additional 142,534 shares during the period. Cellebrite DI comprises 15.7% of Crescent Park Management L.P.’s portfolio, making the stock its 2nd largest holding. Crescent Park Management L.P.’s holdings in Cellebrite DI were worth $41,030,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of CLBT. FMR LLC raised its holdings in Cellebrite DI by 136.3% during the third quarter. FMR LLC now owns 5,616,757 shares of the company’s stock valued at $94,586,000 after acquiring an additional 3,239,307 shares during the period. True Wind Capital Management L.P. grew its position in shares of Cellebrite DI by 18.2% during the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock worth $305,358,000 after purchasing an additional 2,130,386 shares in the last quarter. Principal Financial Group Inc. bought a new stake in Cellebrite DI during the 3rd quarter valued at approximately $23,402,000. Lord Abbett & CO. LLC purchased a new position in Cellebrite DI in the 3rd quarter worth approximately $11,523,000. Finally, Pertento Partners LLP boosted its stake in Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after purchasing an additional 626,373 shares during the period. 45.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on CLBT. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a report on Thursday, March 27th. Finally, Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Cellebrite DI currently has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Stock Down 0.9 %

CLBT stock opened at $19.25 on Wednesday. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The firm has a market capitalization of $4.61 billion, a P/E ratio of -13.85, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. The company has a fifty day simple moving average of $20.71 and a two-hundred day simple moving average of $19.94.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.